| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/13/2013 | CN101768214B Human tumor marker-Tim17 polypeptide and application thereof |
| 03/13/2013 | CN101565446B Veratramine degradation product veratrum fluorene aldehyde and the derivatives thereof, as well as the preparation and application thereof |
| 03/13/2013 | CN101503356B Novel method for preparing high-purity chlorogenic acid |
| 03/13/2013 | CN101415686B Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
| 03/13/2013 | CN101384716B HLA-a*3303-restricted WT1 peptide and pharmaceutical composition comprising the same |
| 03/13/2013 | CN101302256B Novel recombinant fusion molecule and antineoplastic treatment function thereof |
| 03/13/2013 | CN101284133B Drug carried tumor-targeted cationic polymer for injections and modified by integrin ligand |
| 03/13/2013 | CN101142232B KUNITZ-type recombinant inhibitor |
| 03/13/2013 | CN101134779B Antibodies specific for human CD22 and their therapeutic and diagnostic uses |
| 03/13/2013 | CN101130536B Flavanone compound and uses thereof |
| 03/13/2013 | CA2752008A1 Combination therapy using ribavirin as elf4e inhibitor |
| 03/12/2013 | US8394971 Indole derivatives as selective androgen receptor modulators (SARMS) |
| 03/12/2013 | US8394930 Growth factor isoform |
| 03/12/2013 | US8394849 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 03/12/2013 | US8394831 Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 03/12/2013 | US8394786 Quinazoline derivatives |
| 03/12/2013 | US8394757 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| 03/12/2013 | US8394418 Combination preparation of a biological response modifier and an anticancer agent and uses thereof |
| 03/12/2013 | US8394397 Adhesive antineoplastic compositions |
| 03/12/2013 | US8394381 Administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR); inhibiting angiogenesis |
| 03/12/2013 | US8394371 Compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
| 03/12/2013 | US8394369 Chondrocyte therapeutic delivery system |
| 03/12/2013 | US8394368 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 03/12/2013 | CA2731773C Amidophenoxyindazoles useful as inhibitors of c-met |
| 03/12/2013 | CA2706661C Intermediates for the preparation of lipoxin a4 analogs |
| 03/12/2013 | CA2699568C Azaindoles |
| 03/12/2013 | CA2668210C Anilinopiperazine derivatives and methods of use thereof |
| 03/12/2013 | CA2637933C Indole sulfonamide modulators of progesterone receptors |
| 03/12/2013 | CA2603826C Substituted oxazole derivatives and their use as tyrosine kinase inhibitors |
| 03/12/2013 | CA2550350C 2-(hetero)aryl-substituted tetrahydroquinoline derivatives |
| 03/12/2013 | CA2531661C Histone deacetylase inhibitors and methods of use thereof |
| 03/12/2013 | CA2506724C Antibodies, polypeptides and uses thereof |
| 03/12/2013 | CA2497744C Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3 |
| 03/12/2013 | CA2469685C Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 03/12/2013 | CA2468888C Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 03/12/2013 | CA2453561C Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 03/12/2013 | CA2437044C Method of determining a chemotherapeutic regimen based on ercc1 expression |
| 03/12/2013 | CA2407910C Antibodies that immunospecifically bind to blys |
| 03/12/2013 | CA2366787C Compositions and methods for treating lymphoma |
| 03/07/2013 | WO2013033688A1 Treatment of cancer |
| 03/07/2013 | WO2013033636A2 Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same |
| 03/07/2013 | WO2013033626A2 Nkp30 receptor targeted therapeutics |
| 03/07/2013 | WO2013033569A1 Heterocyclylamines as pi3k inhibitors |
| 03/07/2013 | WO2013033518A1 Methods for treating properdin-related diseases or disorders |
| 03/07/2013 | WO2013033345A1 Immunomodulators and immunomodulator conjugates |
| 03/07/2013 | WO2013033324A2 Materials and methods for modulating activity of bone marrow derived cells |
| 03/07/2013 | WO2013033269A1 Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| 03/07/2013 | WO2013033268A2 Bivalent bromodomain ligands, and methods of using same |
| 03/07/2013 | WO2013033260A1 Use of hdl-related molecules to treat and prevent proinflammatory conditions |
| 03/07/2013 | WO2013033176A1 Decitabine derivative formulations |
| 03/07/2013 | WO2013033041A1 Platinum anticancer agents |
| 03/07/2013 | WO2013032960A2 Vitamin d receptor - coregulator inhibitors |
| 03/07/2013 | WO2013032948A1 Method for inhibiting cellular activation by insulin-like growth factor-1 |
| 03/07/2013 | WO2013032905A1 Modulating wnt activity by targeting gpr177 |
| 03/07/2013 | WO2013032846A1 2-METHYLENE-19,23,24-TRINOR-1α-HYDROXYVITAMIN D3 |
| 03/07/2013 | WO2013032028A1 New compound material, medicine containing same, and cancer treatment method using same |
| 03/07/2013 | WO2013032012A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/07/2013 | WO2013032011A1 Glycosylated polypeptide and drug composition containing said polypeptide |
| 03/07/2013 | WO2013031882A1 Vaccine preparation for cancer treatment |
| 03/07/2013 | WO2013031704A1 Heptamer-type small guide nucleic acid capable of inducing apoptosis of human leukemia cell |
| 03/07/2013 | WO2013031003A1 Dna repair accelerator and dna damage suppressant |
| 03/07/2013 | WO2013030778A2 Organic compositions to treat hsf1-related diseases |
| 03/07/2013 | WO2013030602A1 Solid extended release composition for oral administration comprising substantially amorphous capecitabine |
| 03/07/2013 | WO2013030569A2 Peptides |
| 03/07/2013 | WO2013030512A1 Use of compositions having a low polyamine content in the prevention or treatment of adverse effects linked to cancer treatment |
| 03/07/2013 | WO2013030368A1 Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| 03/07/2013 | WO2013030218A1 Selective and reversible inhibitors of ubiquitin specific protease 7 |
| 03/07/2013 | WO2013030205A1 Parp inhibitors |
| 03/07/2013 | WO2013030150A1 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines |
| 03/07/2013 | WO2013029723A1 Novel photoactivatable paclitaxel derivatives and uses thereof, in particular in cellbiology and cancer treatment |
| 03/07/2013 | WO2013029648A1 New aminoacid compounds for treating tumours and autoimmune diseases |
| 03/07/2013 | WO2013029555A1 Lavendustin a derivatives, preparation method and use thereof |
| 03/07/2013 | WO2013029205A1 Cleavable protein of interferon fused with human serum albumin and encoding gene and use thereof |
| 03/07/2013 | WO2013029180A1 Stable peptide-based pace4 inhibitors |
| 03/07/2013 | WO2013029136A1 Tianeptine derivatives, pharmaceutical compositions, use, and method for producing same |
| 03/07/2013 | WO2013029116A1 Method for predicting treatment responsiveness |
| 03/07/2013 | WO2013009690A3 Leukemia stem cell targeting ligands and methods of use |
| 03/07/2013 | WO2013007704A3 Novel sdf-1-based glycosaminoglycan antagonist and methods of using same |
| 03/07/2013 | WO2012154988A3 Fiduciary markers and methods of placement |
| 03/07/2013 | WO2012148538A3 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin |
| 03/07/2013 | WO2012134252A3 Composition for renal cancer treatment and functional food containing cannabis semen extract |
| 03/07/2013 | WO2012134251A3 Composition for pancreatic cancer treatment and composition for cosmetics containing nardostachyos rhizoma extract |
| 03/07/2013 | WO2012134250A3 Composition for renal cancer treatment and composition for cosmetic containing nardostachyos rhizoma extract |
| 03/07/2013 | WO2012134169A3 Composition for lung cancer treatment and functional food containing gleditsiae semen extract |
| 03/07/2013 | WO2012134168A3 Composition for lung cancer treatment and composition for cosmetics containing lysimachiae foenumgraeci herba extract |
| 03/07/2013 | WO2012134167A3 Composition for lung cancer treatment and functional food containing eriobotriae folium extract |
| 03/07/2013 | WO2012134165A3 Composition for lung cancer treatment and composition for cosmetics containing psoraleae semen extract |
| 03/07/2013 | WO2012134164A3 Composition for lung cancer treatment and functional food containing farfarae flos extract |
| 03/07/2013 | WO2012134163A3 Composition for lung cancer treatment and composition for cosmetics containing nardostachyos rhizoma extract |
| 03/07/2013 | WO2012096545A3 Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof |
| 03/07/2013 | WO2012028332A8 Pharmaceutically active compounds as axl inhibitors |
| 03/07/2013 | US20130059930 Diagnostic method |
| 03/07/2013 | US20130059921 Use of essential oil of oregano and of rosewood, or constituents thereof, in the therapeutic treatment of keratoses |
| 03/07/2013 | US20130059916 Biguanide compounds and its use for treating cancer |
| 03/07/2013 | US20130059911 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| 03/07/2013 | US20130059907 Wogonin-containing pharmaceutical composition for inhibiting cancer stem cells growth and application thereof |
| 03/07/2013 | US20130059906 Methods and compositions for influencing tumors using microrna-185 as a tumor suppressor |
| 03/07/2013 | US20130059903 Compositions and Methods for Characterizing Breast Cancer |
| 03/07/2013 | US20130059892 Compositions and Methods for Cancer Detection and Treatment |
| 03/07/2013 | US20130059889 Anhydrous lenalidomide form-i |